4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Lymphedema by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 25 ongoing clinical trials involving Lymphedema
Of the 25 trials,12 trials are in Phase II
Furthermore, 4 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Lymphedema by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Lymphedema, a Hematological disorder. The largest number of ongoing clinical trials for Lymphedema is conducted in the Asia-Pacific region. Europe and the Middle East and Africa are among some of the other prominent regions engaged in Lymphedema-related drug trials.

Lymphedema related clinical trials sponsors

Puretech Health Plc, Odense University Hospital, Universitair Ziekenhuis Brussel, Hematology-Oncology and Stem Cell Transplantation Research Center, and Sun Yat-Sen University Hospital 5 are a few notable clinical trial sponsors involved in Lymphedema. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Lymphedema

Benzocaine and Heparin sodium (Nigepan), Coumarin and Heparin (Venalot H), and Ethacrynic Acid are among the key marketed drugs involving Lymphedema.

Benzocaine and Heparin sodium (Nigepan) is formulated in the form of suppository for the rectal route of administration and ointment for topical application. It functions via Antithrombin III Activator, Voltage-Gated Sodium Channel (SCN) Blocker mechanism of action. It is indicated for the relief of symptoms associated with hemorrhoids (including perianal hematomas), perianal eczema, pruritus, anal fissure, proctitis, periproctitis, and aftercare of hemorrhoids treated by surgery or injection. Benzocaine and Heparin sodium is marketed in Russia by Stada CIS LLC.

Coumarin and Heparin (Venalot H) is a fixed-dose combination, acts as an anticoagulant. It functions via Antithrombin III Activator, Vitamin K Epoxide Reductase Inhibitor mechanism of action. It is formulated as a cream for topical application. Venalot H is indicated for local treatment of venous and lymphatic disorders: varicose syndrome, varicose veins, hemorrhoids, leg ulcers, phlebitis, thrombophlebitis, periflebites, post-phlebitic syndromes, lymphangitis, local circulatory disorders, such as bruises, and adjunctive treatment in severe cases of venous and lymphatic disorders such as lymphedema. Coumarin and Heparin were first approved in 1989 and are marketed in Brazil by Takeda Pharmaceutical Brazil Ltda.